Eli Lilly and Company
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Eli Lilly and Company
Boehringer expects Jardiance’s new chronic kidney disease indication to keep its sales growing by double-digit percentages over the coming years, aided by the drug’s ability to reduce hospitalizations.
The liver disease is one of the hottest areas of drug development. Here are some upcoming catalysts to look out for.
Following a positive opinion from the CHMP, the Spanish company is hoping to launch its challenger to Dupixent in the EU before the end of the year.
BI’s global head of innovation Michel Pairet tells In Vivo that while unmet medical need is the pharma’s R&D priority, its main focus is bringing breakthrough therapy potential to patients, and it is taking aim at competitive spaces like metabolic health and cancer.
- Other Names / Subsidiaries
- Akouos, Inc.
- Alnara Pharmaceuticals, Inc.
- ARMO BioSciences, Inc.
- Applied Molecular Evolution
- Avid Radiopharmaceuticals, Inc.
- Bowfin Acquisition Corporation
- Class AP
- CoLucid Pharmaceuticals, Inc.
- Dermira Inc.
- Disarm Therapeutics, Inc.
- ICOS Corporation
- ImClone Systems
- Loxo Oncology, Inc. (LOXO)
- Protomer Technologies
- SGX Pharmaceuticals (Structural GenomiX)
- Valocor Therapeutics, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.